Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
axitinib, Bermuda, CELESTIAL, clarify, depletion, Eisai, EU, exploit, half, Harbor, hiring, ImClone, insignificant, landscape, lenvatinib, pazopanib, predominantly, processing, promptly, Radium, ramucirumab, regorafenib, Safe, science, secondary, undertaken, wage
Removed:
American, breast, cohort, demonstrated, exploring, implementing, initiate, range, RDT
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Amendment No. 2 DTD 8/1/13 to Deerfield Note Purchase Agreement, DTD 6/2/10
- 10.2 Sublease, DTD 8/5/13, Between Exelixis, Inc. and Sutro Biopharma, Inc.
- 10.3 Consent to Sublease, DTD 8/5/13
- 10.4 Employment Agreement Between Exelixis, Inc. and Pamela A. Simonton
- 31.1 Certification of CEO Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of CFO Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification of CEO and CFO Required by Rule 13A-14(B) or Rule 15D-14(B)
- Download Excel data file
- View Excel data file
Related press release
EXEL similar filings
Filing view
External links